Tags

Type your tag names separated by a space and hit enter

Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
Int J Hematol. 2000 Aug; 72(2):229-36.IJ

Abstract

We compared interferon-alpha (IFN-alpha therapy with bone marrow transplantation (BMT) after initial conventional chemotherapy in patients with chronic myelogenous leukemia (CML) in a multicenter prospective study. Ninety patients with Philadelphia chromosome-positive CML in chronic phase were enrolled between 1991 and 1994. Sixty-six of 89 evaluable patients received IFN-alpha after conventional chemotherapy with hydroxyurea or busulfan (IFN-alpha group). Twenty-three patients received allogeneic BMT (BMT group). Fifteen of them received transplants from HLA-identical family donors and 8 from HLA-matched unrelated donors. Forty-seven of 66 patients (71%) in the IFN-alpha group and 17 of 23 patients (74%) in the BMT group achieved complete hematologic response, and 12% in the IFN-alpha group and 13% in the BMT group achieved partial hematologic response. Complete cytogenetic response was induced in 5 (8%), partial cytogenetic response in 8 (12%), and minor cytogenetic response in 12 (18%) in the IFN-alpha group. At a median follow-up of 54 months (range, 30-76 months), in the IFN-alpha group, the predicted 6-year survival rate was 54.5% and the predicted 6-year rate of those remaining in chronic phase was 45.7%. Compared with patients with no cytogenetic response, the patients with some cytogenetic response after IFN-alpha treatment had significantly superior survival and duration of the chronic phase even after correction for the time to response using landmark analysis (P < .05). In the BMT group, the predicted 5-year survival rate was 93.3% for family-donor BMT and 21.9% for unrelated-donor BMT Acute graft-versus-host disease of grade III or IV was observed in 1 of 15 patients who received family-donor BMT and 3 of 8 patients who received unrelated donor BMT. Prior treatment with conventional cytotoxic drugs induced early hematologic response and did not reduce the effect of IFN-alpha on CML. Unrelated-donor transplantation should be offered to some patients according to patient age, HLA-matching status, time from diagnosis to BMT, and risk factors.

Authors+Show Affiliations

Department of Medicine III, Hamamatsu University School of Medicine, Japan. kohnishi@hama-med.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11039674

Citation

Ohnishi, K, et al. "Multicenter Prospective Study of Interferon-alpha and Conventional Chemotherapy Versus Bone Marrow Transplantation for Newly Diagnosed Patients With Chronic Myelogenous Leukemia. Kouseisho Leukemia Study Group." International Journal of Hematology, vol. 72, no. 2, 2000, pp. 229-36.
Ohnishi K, Minami S, Ueda T, et al. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group. Int J Hematol. 2000;72(2):229-36.
Ohnishi, K., Minami, S., Ueda, T., Nishimura, M., Tsubaki, K., Takemoto, Y., Takeshita, A., Sao, H., Kageyama, S., Ueda, R., & Ohno, R. (2000). Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group. International Journal of Hematology, 72(2), 229-36.
Ohnishi K, et al. Multicenter Prospective Study of Interferon-alpha and Conventional Chemotherapy Versus Bone Marrow Transplantation for Newly Diagnosed Patients With Chronic Myelogenous Leukemia. Kouseisho Leukemia Study Group. Int J Hematol. 2000;72(2):229-36. PubMed PMID: 11039674.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group. AU - Ohnishi,K, AU - Minami,S, AU - Ueda,T, AU - Nishimura,M, AU - Tsubaki,K, AU - Takemoto,Y, AU - Takeshita,A, AU - Sao,H, AU - Kageyama,S, AU - Ueda,R, AU - Ohno,R, PY - 2000/10/20/pubmed PY - 2001/2/28/medline PY - 2000/10/20/entrez SP - 229 EP - 36 JF - International journal of hematology JO - Int J Hematol VL - 72 IS - 2 N2 - We compared interferon-alpha (IFN-alpha therapy with bone marrow transplantation (BMT) after initial conventional chemotherapy in patients with chronic myelogenous leukemia (CML) in a multicenter prospective study. Ninety patients with Philadelphia chromosome-positive CML in chronic phase were enrolled between 1991 and 1994. Sixty-six of 89 evaluable patients received IFN-alpha after conventional chemotherapy with hydroxyurea or busulfan (IFN-alpha group). Twenty-three patients received allogeneic BMT (BMT group). Fifteen of them received transplants from HLA-identical family donors and 8 from HLA-matched unrelated donors. Forty-seven of 66 patients (71%) in the IFN-alpha group and 17 of 23 patients (74%) in the BMT group achieved complete hematologic response, and 12% in the IFN-alpha group and 13% in the BMT group achieved partial hematologic response. Complete cytogenetic response was induced in 5 (8%), partial cytogenetic response in 8 (12%), and minor cytogenetic response in 12 (18%) in the IFN-alpha group. At a median follow-up of 54 months (range, 30-76 months), in the IFN-alpha group, the predicted 6-year survival rate was 54.5% and the predicted 6-year rate of those remaining in chronic phase was 45.7%. Compared with patients with no cytogenetic response, the patients with some cytogenetic response after IFN-alpha treatment had significantly superior survival and duration of the chronic phase even after correction for the time to response using landmark analysis (P < .05). In the BMT group, the predicted 5-year survival rate was 93.3% for family-donor BMT and 21.9% for unrelated-donor BMT Acute graft-versus-host disease of grade III or IV was observed in 1 of 15 patients who received family-donor BMT and 3 of 8 patients who received unrelated donor BMT. Prior treatment with conventional cytotoxic drugs induced early hematologic response and did not reduce the effect of IFN-alpha on CML. Unrelated-donor transplantation should be offered to some patients according to patient age, HLA-matching status, time from diagnosis to BMT, and risk factors. SN - 0925-5710 UR - https://www.unboundmedicine.com/medline/citation/11039674/Multicenter_prospective_study_of_interferon_alpha_and_conventional_chemotherapy_versus_bone_marrow_transplantation_for_newly_diagnosed_patients_with_chronic_myelogenous_leukemia__Kouseisho_Leukemia_Study_Group_ L2 - http://www.diseaseinfosearch.org/result/7171 DB - PRIME DP - Unbound Medicine ER -